5 results on '"Park, S. S."'
Search Results
2. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
- Author
-
Oh SC, Sur HY, Sung HJ, Choi IK, Park SS, Seo JH, Jeen YT, Chun HJ, Shin SW, Mok YJ, Kim JS, and Kim YH
- Subjects
- Adenocarcinoma pathology, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Camptothecin administration & dosage, Camptothecin adverse effects, Capecitabine, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Humans, Irinotecan, Male, Middle Aged, Neoplasm Metastasis, Stomach Neoplasms pathology, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin analogs & derivatives, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives, Stomach Neoplasms drug therapy
- Abstract
Capecitabine, a prodrug of 5-FU, has been reported to generate maximal tumour activity at tumour sites and/or to improve drug tolerability as compared with 5-FU infusion, and it has also been demonstrated to act synergistically with irinotecan against some solid cancers. A previous study concluded that dose-intensified biweekly capecitabine seems to be more effective at increasing both response rate and progression-free survival time than conventional dose and schedule of capecitabine in colon cancer. We conducted this study to ascertain the efficacy and toxicity of dose-intensified biweekly capecitabine and irinotecan combination chemotherapy in chemotherapy-naïve advanced or metastatic gastric cancer patients. Patients were treated with irinotecan 130 mg m(-2) intravenously for 90 min on days 1 and 15. Capecitabine at 3500 mg m(-2) day(-1), divided into two sessions per day, was administered for seven consecutive days from days 1 and 15, and followed by a 7-day drug-free period, respectively. Fifty-five eligible patients were enrolled in this study from November 2003 to April 2006. There were 22 women and 33 men: median patient age was 54 years (range: 27-81). A total of 200 treatment cycles were administered at a median number of four per patient (range: 1-9). Intent-to-treatment analysis showed that one patient achieved complete response (1.8%), 23 partial response (41.8%), 15 stable disease (27.3%), 10 progressive disease (18.2%) and 6 were non-evaluable (10.9%). The overall response rate was 43.6% (95% confidence interval: 30.2-56.9). The common grade 3-4 toxicities were neutropenia in 12 (21.8%), nausea/vomiting in 3 (5.4%) and diarrhea in 4 (7.2%) patients. Median time to progression was 5 months (range: 0.5-11 months), median survival duration was 11 months (range: 0.5-45 months) and median response duration was 6 months (range: 0.5-9 months). Biweekly dose-intensified capecitabine and irinotecan combination chemotherapy was active for the treatment of advanced or metastatic gastric cancers with a tolerable safety profile.
- Published
- 2007
- Full Text
- View/download PDF
3. Double cancer of the stomach and oesophagus with situs ambiguus with polysplenia: the importance of preoperative evaluation.
- Author
-
Park SS, Min BW, Kim WB, Han HJ, Yong HS, Kim SJ, Kim CS, and Mok YJ
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma surgery, Biomarkers, Tumor blood, CA-19-9 Antigen blood, Carcinoembryonic Antigen blood, Endoscopy, Gastrointestinal, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms surgery, Gastrectomy, Gastroenterostomy, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Multiple Primary diagnostic imaging, Neoplasms, Multiple Primary surgery, Situs Inversus diagnostic imaging, Situs Inversus surgery, Splenic Diseases complications, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms surgery, Tomography, X-Ray Computed, Adenocarcinoma diagnosis, Esophageal Neoplasms diagnosis, Neoplasms, Multiple Primary diagnosis, Preoperative Care, Situs Inversus diagnosis, Spleen abnormalities, Stomach Neoplasms diagnosis
- Abstract
A rare case of double cancer with situs ambiguus with polysplenia is presented. A 58-year-old patient was initially diagnosed with an early gastric cancer. On evaluation, the computed tomography of the abdomen demonstrated situs ambiguus with polysplenia. We performed a subtotal gastrectomy with the stomach being reconstructed in a Billroth-II fashion. Three months after the operation, he again visited our department complaining nausea and dysphagia. Examinations confirmed the other oesophageal malignancy with advanced stage. Because of unfamiliarity to situs anomaly and rarity of double cancer, we missed the other coexistent cancer. This is the first case presentation of a double carcinoma occurring in a patient with situs ambiguus with polysplenia. The literature is reviewed and the importance of preoperative evaluation is discussed.
- Published
- 2005
- Full Text
- View/download PDF
4. Colorectal adenocarcinoma as a second malignant neoplasm following rhabdomyosarcoma of the urinary bladder: a case report.
- Author
-
Park SS, Kim BK, Kim CJ, Kim WS, Kim IO, Park KW, Shin HY, and Ahn HS
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colitis etiology, Colitis pathology, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Doxorubicin administration & dosage, Doxorubicin adverse effects, Genes, p53, Humans, Male, Neoplasm Proteins analysis, Neoplasms, Radiation-Induced genetics, Neoplasms, Radiation-Induced pathology, Radiation Injuries etiology, Radiation Injuries pathology, Sigmoid Neoplasms etiology, Sigmoid Neoplasms genetics, Sigmoid Neoplasms pathology, Time Factors, Tumor Suppressor Protein p53 analysis, Vincristine administration & dosage, Vincristine adverse effects, Adenocarcinoma etiology, Antineoplastic Combined Chemotherapy Protocols adverse effects, Colorectal Neoplasms etiology, Neoplasms, Radiation-Induced etiology, Neoplasms, Second Primary etiology, Radiotherapy adverse effects, Rhabdomyosarcoma drug therapy, Rhabdomyosarcoma radiotherapy, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms radiotherapy
- Abstract
Following improvements in therapy for childhood malignancies, the striking increase in survival rate over the past 30 years has led to the increase risk of developing second malignant neoplasms (SMNs). We report a case of colorectal carcinoma as a SMN, following treatment for rhabdomyosarcoma. The patient was diagnosed with rhabdomyosarcoma of the urinary bladder at his age of three years, and developed adenocarcinoma in the colon 13 years later. Histologic examination of the surgical specimen revealed adenocarcinoma involving the rectosigmoid area with radiation colitis in its background. The tumor cells showed strong immunoreactivity for p53 protein, suggesting the role of irradiation and p53 mutation in carcinogenesis. This case emphasizes the need for dose observation in survivors of early childhood malignancies treated with radiation and multiagent chemotherapy.
- Published
- 2000
- Full Text
- View/download PDF
5. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients.
- Author
-
Anttila S, Hietanen E, Vainio H, Camus AM, Gelboin HV, Park SS, Heikkilä L, Karjalainen A, and Bartsch H
- Subjects
- Aryl Hydrocarbon Hydroxylases analysis, Bronchi enzymology, Carcinoma, Small Cell enzymology, Carcinoma, Squamous Cell enzymology, Female, Humans, Immunohistochemistry, Isoenzymes, Lung enzymology, Male, Adenocarcinoma enzymology, Cytochrome P-450 Enzyme System analysis, Lung Neoplasms enzymology, Smoking adverse effects
- Abstract
A specific member of the cytochrome P450 superfamily of enzymes, designated P450IA (including 2 isozymes, P450IA1 and P450IA2), which is involved in the metabolic activation of polycyclic aromatic hydrocarbons and aromatic amines, was studied in lung tissue from 25 lung cancer patients by immunohistochemistry. The pulmonary activity of a P450IA1-dependent enzyme, aryl hydrocarbon hydroxylase (AHH), from the same patients was also measured. Cytochrome P450IA was localized principally in the peripheral airways in alveolar epithelium of types I and II and in ciliated columnar and cuboidal bronchiolar epithelium. The amount of P450IA in the bronchial wall was minimal and was localized mainly in the capillary endothelium and the epithelium of the bronchial glands. Smoking was the most important factor related to the presence of P450IA and the AHH activity in lung tissue. None of the 10 ex-smokers, but all except I of the current smokers had detectable level of P450IA. The localization of the cancer was also correlated with the presence of cytochrome P450IA. Peripheral lung tissue stained positively in all patients with a peripheral adenocarcinoma who currently smoked (8/8) but in less than half of those with a bronchial cancer who were smokers (3/7). Our data suggest that the smokers who have an inducible cytochrome P450IA are especially at increased risk of developing lung cancer of the peripheral adenocarcinomatous type.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.